Single User License
INR 237755
Site License
INR 475510
Corporate User License
INR 713265

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Gamma Secretase (EC 3.4.23.)-Pipeline Review, H2 2016

Gamma Secretase (EC 3.4.23.)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Gamma Secretase (EC 3.4.23.)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Gamma Secretase (EC 3.4.23.)-Pipeline Review, H2 2016', provides in depth analysis on Gamma Secretase (EC 3.4.23.) targeted pipeline therapeutics.

The report provides comprehensive information on the Gamma Secretase (EC 3.4.23.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)

The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects

The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Gamma Secretase (EC 3.4.23.) Overview 8

Therapeutics Development 9

Gamma Secretase (EC 3.4.23.)-Products under Development by Stage of Development 9

Gamma Secretase (EC 3.4.23.)-Products under Development by Therapy Area 10

Gamma Secretase (EC 3.4.23.)-Products under Development by Indication 11

Gamma Secretase (EC 3.4.23.)-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Gamma Secretase (EC 3.4.23.)-Products under Development by Companies 14

Gamma Secretase (EC 3.4.23.)-Products under Development by Universities/Institutes 16

Gamma Secretase (EC 3.4.23.)-Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 22

Gamma Secretase (EC 3.4.23.)-Companies Involved in Therapeutics Development 23

Amgen Inc. 23

Astellas Pharma Inc. 24

Bristol-Myers Squibb Company 25

Critical Outcome Technologies Inc. 26

FORUM Pharmaceuticals Inc. 27

Lipopharma Therapeutics SL 28

Merck & Co., Inc. 29

NeuroGenetic Pharmaceuticals, Inc. 30

Pfizer Inc. 31

Stemline Therapeutics, Inc. 32

Sumitomo Dainippon Pharma Co., Ltd. 33

Takeda Pharmaceutical Company Limited 34

Gamma Secretase (EC 3.4.23.)-Drug Profiles 35

AS-2715348-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

BMS-932481-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

BMS-986133-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

GSI-34-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

LP-226A1-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

MK-0752-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

MRK-003-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

NGP-328-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

NGP-555-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

nirogacestat-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

SL-301-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

SL-302-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules to Inhibit Ap1B Gamma-Secretase for Alzheimer's Disease-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules to Inhibit Gamma Secretase for Hearing Loss-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Gamma Secretase (EC 3.4.23.)-Dormant Projects 60

Gamma Secretase (EC 3.4.23.)-Discontinued Products 63

Gamma Secretase (EC 3.4.23.)-Featured News & Press Releases 65

Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer's Disease; Reports Initial Results of Phase 1a Clinical Trial 65

Sep 29, 2014: FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimer's Disease 65

Jul 15, 2011: NeuroGenetic Pharma Receives SBIR Grant For Preclinical Development And IND Application Of NGP 555 To Treat Alzheimer's Disease 65

Jul 21, 2009: Critical Outcome Technologies Inc. Announces the Launch of a Drug Discovery Program for Alzheimer's disease 66

Appendix 67

Methodology 67

Coverage 67

Secondary Research 67

Primary Research 67

Expert Panel Validation 67

Contact Us 67

Disclaimer 68

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 22

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Amgen Inc., H2 2016 23

Pipeline by Astellas Pharma Inc., H2 2016 24

Pipeline by Bristol-Myers Squibb Company, H2 2016 25

Pipeline by Critical Outcome Technologies Inc., H2 2016 26

Pipeline by FORUM Pharmaceuticals Inc., H2 2016 27

Pipeline by Lipopharma Therapeutics SL, H2 2016 28

Pipeline by Merck & Co., Inc., H2 2016 29

Pipeline by NeuroGenetic Pharmaceuticals, Inc., H2 2016 30

Pipeline by Pfizer Inc., H2 2016 31

Pipeline by Stemline Therapeutics, Inc., H2 2016 32

Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 33

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 34

Dormant Projects, H2 2016 60

Dormant Projects (Contd..1), H2 2016 61

Dormant Projects (Contd..2), H2 2016 62

Discontinued Products, H2 2016 63

Discontinued Products (Contd..1), H2 2016 64

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Critical Outcome Technologies Inc., FORUM Pharmaceuticals Inc., Lipopharma Therapeutics SL, Merck & Co., Inc., NeuroGenetic Pharmaceuticals, Inc., Pfizer Inc., Stemline Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited

Gamma Secretase (EC 3.4.23.) Therapeutic Products under Development, Key Players in Gamma Secretase (EC 3.4.23.) Therapeutics, Gamma Secretase (EC 3.4.23.) Pipeline Overview, Gamma Secretase (EC 3.4.23.) Pipeline, Gamma Secretase (EC 3.4.23.) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com